Covid-19 Drug Prevents Symptomatic Disease in Study, Regeneron Says An antibody drug from Regeneron Pharmaceuticals Inc. reduced the risk of developing symptomatic Covid-19 infection by 81% compared with a placebo in people living with someone infected by the new coronavirus, a study found.
PHASE 3 TRIAL SHOWS REGEN-COV™ (CASIRIVIMAB WITH IMDEVIMAB) ANTIBODY COCKTAIL REDUCED HOSPITALIZATION OR DEATH BY 70% IN NON-HOSPITALIZED COVID-19 PATIENTS
Ark is performing these studies and after enrolling hundreds of patients , we can attest to the power of these treatments in preventing severe disease.
Johnson & Johnson’s single-dose vaccine provides strong shield against severe COVID
Johnson & Johnson’s one-shot vaccine generated strong protection against Covid-19 in a large, late-stage trial, raising hopes that it can rapidly reshape a stumbling immunization campaign.
Read in Bloomberg:
Because of excellent data with the Regeneron monoclonal antibody study, the 2067 protocol will now be eliminating the placebo arm.
Will We Have to Wear Masks Forever? Innovation Advisor Dr. Kenneth Kim Weighs in on the COVID-19 Vaccines
Dr. Kim shares his thoughts on a ABC vaccine panel on reaching the Latino community this past week.
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
REGENERON REPORTS POSITIVE INTERIM DATA WITH REGEN-COV™ ANTIBODY COCKTAIL USED AS PASSIVE VACCINE TO PREVENT COVID-19
We have been running this trial for the last several months at Ark Clinical Research, and it is nothing short of amazing results. We have not seen anyone get sick who entered the trial get sick, and this report shows 100% prevention of symptomatic infection among family who took the drug!
Analysis: My Covid-19 vaccine trial experience remains vital as vaccination rates are lagging
Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
What’s Happening With Johnson & Johnson’s Covid-19 Vaccine?